Added to YB: 2026-09-15
Pitch date: 2026-09-12
MBRX [neutral]
Moleculin Biotech, Inc.
+3.33%
current return
Author Info
No bio for this author
Company Info
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses.
Market Cap
$13.9M
Pitch Price
$0.75
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.24
P/E
-0.07
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Biotech Conference Coverage day 4 session 3 - Moleculin Biotech, Inc.
MBRX (quick overview): At ~$0.73, Moleculin is a high-risk AML catalyst trade built around Annamycin, a potentially non-cardiotoxic anthracycline. Initial randomized data showed 39% pooled complete remission versus 12% for control after one cycle, while no cardiotoxicity was detected across 90+ reviewed patients. The thesis requires replication in the 90-patient Part A readout in late 2026 or early 2027, durable outcomes, continued cardiac safety and manageable financing through Part B.
Read full article (2 min)